{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T02:09:24Z","timestamp":1790647764865,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T00:00:00Z","timestamp":1656892800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s11899-022-00667-3","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:11:17Z","timestamp":1656936677000},"page":"113-120","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Germline and Somatic Defects in DDX41 and its Impact on Myeloid Neoplasms"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Chlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,4]]},"reference":[{"key":"667_CR1","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/j.1365-2141.2007.06909.x","volume":"140","author":"C Owen","year":"2008","unstructured":"Owen C, Barnett M, Fitzgibbon J. Familial myelodysplasia and acute myeloid leukaemia\u2014a review. Br J Haematol. 2008;140:123\u201332. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06909.x.","journal-title":"Br J Haematol"},{"key":"667_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391\u2013405. https:\/\/doi.org\/10.1182\/blood-2016-03-643544.","journal-title":"Blood"},{"key":"667_CR3","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1182\/blood.2019000909","volume":"134","author":"M S\u00e9bert","year":"2019","unstructured":"S\u00e9bert M, et al. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019;134:1441\u20134. https:\/\/doi.org\/10.1182\/blood.2019000909.","journal-title":"Blood"},{"key":"667_CR4","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.seminhematol.2017.04.007","volume":"54","author":"JP Maciejewski","year":"2017","unstructured":"Maciejewski JP, Padgett RA, Brown AL, M\u00fcller-Tidow C. DDX41-related myeloid neoplasia. Semin Hematol. 2017;54:94\u20137. https:\/\/doi.org\/10.1053\/j.seminhematol.2017.04.007.","journal-title":"Semin Hematol"},{"key":"667_CR5","doi-asserted-by":"publisher","first-page":"34756","DOI":"10.1038\/srep34756","volume":"6","author":"H Omura","year":"2016","unstructured":"Omura H, et al. Structural and functional analysis of DDX41: a bispecific immune receptor for DNA and cyclic dinucleotide. Sci Rep. 2016;6:34756. https:\/\/doi.org\/10.1038\/srep34756.","journal-title":"Sci Rep"},{"key":"667_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert C, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658\u201370. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.017.","journal-title":"Cancer Cell"},{"key":"667_CR7","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1002\/ajh.25610","volume":"95","author":"I Abou Dalle","year":"2020","unstructured":"Abou Dalle I, et al. Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation. Am J Hematol. 2020;95:227\u20139. https:\/\/doi.org\/10.1002\/ajh.25610.","journal-title":"Am. J. Hematol."},{"key":"667_CR8","doi-asserted-by":"publisher","first-page":"204062072110324","DOI":"10.1177\/20406207211032433","volume":"12","author":"Z Wan","year":"2021","unstructured":"Wan Z, Han B. Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data. Ther Adv Hematol. 2021;12:20406207211032430. https:\/\/doi.org\/10.1177\/20406207211032433.","journal-title":"Ther Adv Hematol"},{"key":"667_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","volume":"6","author":"HB Alkhateeb","year":"2022","unstructured":"Alkhateeb HB, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022;6:528\u201332. https:\/\/doi.org\/10.1182\/bloodadvances.2021005738.","journal-title":"Blood Adv"},{"key":"667_CR10","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1002\/ajh.25486","volume":"94","author":"AE Quesada","year":"2019","unstructured":"Quesada AE, et al. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019;94:757\u201366. https:\/\/doi.org\/10.1002\/ajh.25486.","journal-title":"Am J Hematol"},{"key":"667_CR11","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3324\/haematol.2020.270553","volume":"107","author":"EJ Choi","year":"2022","unstructured":"Choi EJ, et al. Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica. 2022;107:510\u20138. https:\/\/doi.org\/10.3324\/haematol.2020.270553.","journal-title":"Haematologica"},{"key":"667_CR12","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1182\/blood-2015-10-676098","volume":"127","author":"M Lewinsohn","year":"2016","unstructured":"Lewinsohn M, et al. Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood. 2016;127:1017\u201323. https:\/\/doi.org\/10.1182\/blood-2015-10-676098.","journal-title":"Blood"},{"key":"667_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2021.198352","volume":"296","author":"MAM Ali","year":"2021","unstructured":"Ali MAM. DEAD-box RNA helicases: the driving forces behind RNA metabolism at the crossroad of viral replication and antiviral innate immunity. Virus Res. 2021;296: 198352. https:\/\/doi.org\/10.1016\/j.virusres.2021.198352.","journal-title":"Virus Res"},{"key":"667_CR14","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/ni.2091","volume":"12","author":"Z Zhang","year":"2011","unstructured":"Zhang Z, et al. The helicase DDX41 senses intracellular DNA mediated by the adaptor STING in dendritic cells. Nat Immunol. 2011;12:959\u201365. https:\/\/doi.org\/10.1038\/ni.2091.","journal-title":"Nat Immunol"},{"key":"667_CR15","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1038\/ni.2460","volume":"13","author":"K Parvatiyar","year":"2012","unstructured":"Parvatiyar K, et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat Immunol. 2012;13:1155. https:\/\/doi.org\/10.1038\/ni.2460.","journal-title":"Nat Immunol"},{"key":"667_CR16","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/j.celrep.2015.01.039","volume":"10","author":"KG Lee","year":"2015","unstructured":"Lee KG, et al. Bruton\u2019s tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response. Cell Rep. 2015;10:1055\u201365. https:\/\/doi.org\/10.1016\/j.celrep.2015.01.039.","journal-title":"Cell Rep"},{"key":"667_CR17","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.chom.2015.02.021","volume":"17","author":"S Stavrou","year":"2015","unstructured":"Stavrou S, Blouch K, Kotla S, Bass A, Ross SR. Nucleic acid recognition orchestrates the anti-viral response to retroviruses. Cell Host Microbe. 2015;17:478\u201388. https:\/\/doi.org\/10.1016\/j.chom.2015.02.021.","journal-title":"Cell Host Microbe"},{"key":"667_CR18","doi-asserted-by":"publisher","unstructured":"Stavrou, S., Aguilera, A. N., Blouch, K. & Ross, S. R. DDX41 recognizes RNA\/DNA retroviral reverse transcripts and is critical for in vivo control of murine leukemia virus infection. mBio (2018) 9, https:\/\/doi.org\/10.1128\/mBio.00923-18.","DOI":"10.1128\/mBio.00923-18"},{"key":"667_CR19","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.devcel.2021.02.006","volume":"56","author":"JT Weinreb","year":"2021","unstructured":"Weinreb JT, et al. Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production. Dev Cell. 2021;56:627-640.e625. https:\/\/doi.org\/10.1016\/j.devcel.2021.02.006.","journal-title":"Dev Cell"},{"key":"667_CR20","doi-asserted-by":"publisher","first-page":"7314","DOI":"10.1038\/s41467-021-27530-y","volume":"12","author":"T Mosler","year":"2021","unstructured":"Mosler T, et al. R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability. Nat Commun. 2021;12:7314. https:\/\/doi.org\/10.1038\/s41467-021-27530-y.","journal-title":"Nat Commun"},{"key":"667_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2020.257246","volume":"107","author":"JT Weinreb","year":"2022","unstructured":"Weinreb JT, Gupta V, Sharvit E, Weil R, Bowman TV. Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish. Haematologica. 2022;107:644\u201354. https:\/\/doi.org\/10.3324\/haematol.2020.257246.","journal-title":"Haematologica"},{"key":"667_CR22","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","volume":"27","author":"C Polprasert","year":"2015","unstructured":"Polprasert C, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015;27:658\u201370. https:\/\/doi.org\/10.1016\/j.ccell.2015.03.017.","journal-title":"Cancer Cell"},{"key":"667_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2021.08.004","author":"TM Chlon","year":"2021","unstructured":"Chlon TM, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021. https:\/\/doi.org\/10.1016\/j.stem.2021.08.004.","journal-title":"Cell Stem Cell"},{"key":"667_CR24","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.exphem.2016.04.017","volume":"44","author":"M Kadono","year":"2016","unstructured":"Kadono M, et al. Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia. Exp Hematol. 2016;44:745-754.e744. https:\/\/doi.org\/10.1016\/j.exphem.2016.04.017.","journal-title":"Exp. Hematol."},{"key":"667_CR25","doi-asserted-by":"publisher","first-page":"204062072110324","DOI":"10.1177\/20406207211032433","volume":"12","author":"Z Wan","year":"2021","unstructured":"Wan Z, Han B. Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data. Therapeutic Advances in Hematology. 2021;12:20406207211032430. https:\/\/doi.org\/10.1177\/20406207211032433.","journal-title":"Therapeutic Advances in Hematology"},{"key":"667_CR26","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.270553","author":"EJ Choi","year":"2021","unstructured":"Choi EJ, et al. Unique ethnic features of DDX41 mutations in patients with idiopathic cytopenia of undetermined significance, myelodysplastic syndrome, or acute myeloid leukemia. Haematologica. 2021. https:\/\/doi.org\/10.3324\/haematol.2020.270553.","journal-title":"Haematologica"},{"key":"667_CR27","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s12185-019-02770-3","volume":"111","author":"C Polprasert","year":"2020","unstructured":"Polprasert C, et al. Novel DDX41 variants in Thai patients with myeloid neoplasms. Int J Hematol. 2020;111:241\u20136. https:\/\/doi.org\/10.1007\/s12185-019-02770-3.","journal-title":"Int J Hematol"},{"key":"667_CR28","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature13035","volume":"509","author":"RA Signer","year":"2014","unstructured":"Signer RA, Magee JA, Salic A, Morrison SJ. Haematopoietic stem cells require a highly regulated protein synthesis rate. Nature. 2014;509:49\u201354. https:\/\/doi.org\/10.1038\/nature13035.","journal-title":"Nature"},{"key":"667_CR29","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.stem.2021.08.004","volume":"28","author":"TM Chlon","year":"2021","unstructured":"Chlon TM, et al. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021;28:1966-1981.e1966. https:\/\/doi.org\/10.1016\/j.stem.2021.08.004.","journal-title":"Cell Stem Cell"},{"key":"667_CR30","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/leu.2017.44","volume":"31","author":"S Kobayashi","year":"2017","unstructured":"Kobayashi S, et al. Donor cell leukemia arising from preleukemic clones with a novel germline DDX41 mutation after allogenic hematopoietic stem cell transplantation. Leukemia. 2017;31:1020\u20132. https:\/\/doi.org\/10.1038\/leu.2017.44.","journal-title":"Leukemia"},{"key":"667_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1200\/JCO.21.02286","volume":"40","author":"CJ Gibson","year":"2021","unstructured":"Gibson CJ, et al. Donor clonal hematopoiesis and recipient outcomes after transplantation. J Clin Oncol. 2021;40:189\u2013201. https:\/\/doi.org\/10.1200\/JCO.21.02286.","journal-title":"J Clin Oncol"},{"key":"667_CR32","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/leu.2016.310","volume":"31","author":"G Berger","year":"2016","unstructured":"Berger G, et al. Re-emergence of acute myeloid leukemia in donor cells following allogeneic transplantation in a family with a germline DDX41 mutation. Leukemia. 2016;31:520. https:\/\/doi.org\/10.1038\/leu.2016.310.","journal-title":"Leukemia"},{"key":"667_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01404-0","author":"P Li","year":"2021","unstructured":"Li P, et al. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia. 2021. https:\/\/doi.org\/10.1038\/s41375-021-01404-0.","journal-title":"Leukemia"},{"key":"667_CR34","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005738","author":"HB Alkhateeb","year":"2021","unstructured":"Alkhateeb HB, et al. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2021. https:\/\/doi.org\/10.1182\/bloodadvances.2021005738.","journal-title":"Blood Adv"},{"key":"667_CR35","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/leu.2016.228","volume":"30","author":"E Negoro","year":"2016","unstructured":"Negoro E, et al. Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide. Leukemia. 2016;30:2405\u20139. https:\/\/doi.org\/10.1038\/leu.2016.228.","journal-title":"Leukemia"},{"key":"667_CR36","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1182\/blood-2018-99-114681","volume":"132","author":"YF Madanat","year":"2018","unstructured":"Madanat YF, et al. Genomic biomarkers predict response\/resistance to lenalidomide in non-Del(5q) myelodysplastic syndromes. Blood. 2018;132:1797. https:\/\/doi.org\/10.1182\/blood-2018-99-114681.","journal-title":"Blood"},{"key":"667_CR37","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.3324\/haematol.2015.139790","volume":"101","author":"R Li","year":"2016","unstructured":"Li R, Sobreira N, Witmer PD, Pratz KW, Braunstein EM. Two novel germline DDX41 mutations in a family with inherited myelodysplasia\/acute myeloid leukemia. Haematologica. 2016;101:e228-231. https:\/\/doi.org\/10.3324\/haematol.2015.139790.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00667-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11899-022-00667-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-022-00667-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,22]],"date-time":"2022-09-22T12:48:18Z","timestamp":1663850898000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11899-022-00667-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,4]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["667"],"URL":"https:\/\/doi.org\/10.1007\/s11899-022-00667-3","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,4]]},"assertion":[{"value":"19 June 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent."}}]}}